(rel)-Tivantinib ((rel)-ARQ 197; (rel)-(3R,4R)-ARQ 198) 中文名称: (rel)-替万替尼

别名: REL-(3R,4R)-3-(5,6-二氢-4H-吡咯并[3,2,1-IJ]喹啉-1-基)-4-(1H-吲哚-3-基)-2,5-吡咯烷二酮

目录号: V61032 纯度: ≥98%

COA 产品数据产品说明书 SDS

(rel)-Tivantinib（化合物 9）是受体酪氨酸激酶 c-MET 的有效选择性抑制剂。

(rel)-Tivantinib ((rel)-ARQ 197; (rel)-(3R,4R)-ARQ 198) CAS号: 905853-99-8
产品类别: Others 12

产品仅用于科学研究，不针对患者销售

规格	价格
50mg
100mg
Other Sizes

大包装询价

020-31522723 sales@invivochem.cn

Other Forms of (rel)-Tivantinib ((rel)-ARQ 197; (rel)-(3R,4R)-ARQ 198):

点击了解更多

InvivoChem产品被CNS等顶刊论文引用

Nature 2025, 643(8070):192-200.

Nature 2024 Dec 18.

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nat Neurosci 2024, 27:1468-1474.

Science Adv 2025, 11(33):eadr5199.

Nat Metab 2024, 6: 1108-1127.

Cell Stem Cell 2024, 31:106-126.e13.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

Immunity 2024,57:2651-2668.e12.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

产品描述
生物活性&实验参考方法
化学信息
溶解度数据
计算器
临床试验信息
相关产品

产品描述

(rel)-Tivantinib（化合物 9）是受体酪氨酸激酶 c-MET 的有效选择性抑制剂。 (rel)-Tivantinib 有两个新靶点：GSK3α 和 GSK3β，它们在非小细胞肺癌 (NSCLC) 的细胞作用机制中发挥重要作用。

生物活性&实验参考方法

参考文献	[1]. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol. 2014 Feb 21;9(2):353-8.
其他信息	LSM-1131 属于吲哚类化合物。替万替尼已在实体瘤中进行过研究。替万替尼是一种口服生物利用度高的小分子 c-Met 抑制剂，具有潜在的抗肿瘤活性。c-Met 抑制剂 ARQ 197 与 c-Met 蛋白结合，破坏 c-Met 信号转导通路，这可能诱导过表达 c-Met 蛋白或组成型激活 c-Met 蛋白的肿瘤细胞死亡。c-Met 蛋白是原癌基因 c-Met 的产物，是一种受体酪氨酸激酶，也称为肝细胞生长因子受体 (HGFR)。这种蛋白质在多种肿瘤细胞类型中过度表达或发生突变，并在肿瘤细胞增殖、存活、侵袭、转移和肿瘤血管生成中发挥关键作用。药物适应症治疗肝母细胞瘤作用机制替万替尼通过抑制c-Met的活性发挥作用。c-Met是一种受体酪氨酸激酶，在人类癌症中发挥多种关键作用，包括癌细胞生长、存活、血管生成、侵袭和转移。c-Met在大多数癌症中异常激活，被认为控制着参与肿瘤生长和转移的多种信号转导通路。

参考文献

[1]. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol. 2014 Feb 21;9(2):353-8.

其他信息

LSM-1131 属于吲哚类化合物。
替万替尼已在实体瘤中进行过研究。
替万替尼是一种口服生物利用度高的小分子 c-Met 抑制剂，具有潜在的抗肿瘤活性。c-Met 抑制剂 ARQ 197 与 c-Met 蛋白结合，破坏 c-Met 信号转导通路，这可能诱导过表达 c-Met 蛋白或组成型激活 c-Met 蛋白的肿瘤细胞死亡。c-Met 蛋白是原癌基因 c-Met 的产物，是一种受体酪氨酸激酶，也称为肝细胞生长因子受体 (HGFR)。这种蛋白质在多种肿瘤细胞类型中过度表达或发生突变，并在肿瘤细胞增殖、存活、侵袭、转移和肿瘤血管生成中发挥关键作用。

药物适应症
治疗肝母细胞瘤

作用机制
替万替尼通过抑制c-Met的活性发挥作用。c-Met是一种受体酪氨酸激酶，在人类癌症中发挥多种关键作用，包括癌细胞生长、存活、血管生成、侵袭和转移。c-Met在大多数癌症中异常激活，被认为控制着参与肿瘤生长和转移的多种信号转导通路。

*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性

化学信息 & 存储运输条件

分子式	C23H19N3O2
分子量	369.415865182877
精确质量	369.147
CAS号	905853-99-8
相关CAS号	Tivantinib;905854-02-6;(3S,4S)-Tivantinib;905854-03-7;(Rac)-Tivantinib;1239986-50-5
PubChem CID	11494412
外观&性状	Off-white to pink solid powder
密度	1.49±0.1 g/cm3(Predicted)
沸点	715.9±60.0 °C(Predicted)
闪点	386.8±32.9 °C
蒸汽压	0.0±2.3 mmHg at 25°C
折射率	1.797
LogP	3.26
tPSA	66.9
氢键供体(HBD)数目	2
氢键受体(HBA)数目	2
可旋转键数目(RBC)	2
重原子数目	28
分子复杂度/Complexity	666
定义原子立体中心数目	2
SMILES	O=C1NC(=O)[C@@H](C2=CNC3C=CC=CC2=3)[C@@H]1C1=CN2CCCC3C2=C1C=CC=3
InChi Key	UCEQXRCJXIVODC-PMACEKPBSA-N
InChi Code	InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1
化学名	(3R,4R)-3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione
HS Tariff Code	2934.99.9001
存储方式	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
运输条件	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

溶解度数据

溶解度 (体外实验)	May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
溶解度 (体内实验)	注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。注射用配方 (IP/IV/IM/SC等) 注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline) 生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。注射用配方 2:* DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline) 注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil) 示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。 View More 注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)] 20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。注射用配方 5:* 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline) 注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline) 注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) 注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil) 注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline) 口服配方口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠) 口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素) 示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。 View More 口服配方 3: 溶解于 PEG400 (聚乙二醇400) 口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素) 口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素) 口服配方 6: 做成粉末与食物混合注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、以上所有助溶剂都可在 Invivochem.cn网站购买。

溶解度 (体外实验)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

溶解度 (体内实验)

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

注射用配方
(IP/IV/IM/SC等)

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

口服配方

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、以上所有助溶剂都可在 Invivochem.cn网站购买。

制备储备液		1 mg	5 mg	10 mg
	1 mM	2.7069 mL	13.5347 mL	27.0695 mL
	5 mM	0.5414 mL	2.7069 mL	5.4139 mL
	10 mM	0.2707 mL	1.3535 mL	2.7069 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器

质量

浓度

体积

分子量*

计算重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

计算制备已知体积和浓度的溶液所需的化合物的质量
计算将已知质量的化合物溶解到所需浓度所需的溶液体积
计算特定体积中已知质量的化合物产生的溶液的浓度

参见示例

使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？

在分子量（MW）框中输入350.26
在“浓度”框中输入10，然后选择正确的单位（mM）
在“体积”框中输入5，然后选择正确的单位（mL）
单击“计算”按钮
答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。

浓度 (起始)

体积 (起始)

浓度 (终)

体积 (终)

计算重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：

在C1框中输入10，然后选择正确的单位（mM）
在C2框中输入25，然后选择正确的单位（μM）
在V2框中输入25，然后选择正确的单位（mL）
单击“计算”按钮
答案62.5μL（0.1 ml）出现在V1框中

分子式

分子量

g/mol

计算重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4 c12h18n3o4
计算化合物摩尔质量（分子量）的说明：

要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。

分子质量、分子量、摩尔质量和摩尔量的定义：

分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。

配液体积

质量

配液浓度

计算重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

输入试剂的质量、所需的配液浓度以及正确的单位
单击“计算”按钮
答案显示在体积框中

动物体内实验配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg

动物平均体重 g

每只动物给药体积 μL

动物数量

第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。

% DMSO

% Tween 80

% ddH₂O

计算重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意： (1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息

Title:Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)
Status:Completed
updateDate:2025-05-23
Ctid:NCT06987942

Link: https://clinicaltrials.gov/ct2/show/NCT06987942

Conditions:Varicella|Influenza Vaccine
Interventions:TIV
Phase:Phase 4

Title:Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction
Status:Completed
updateDate:2024-12-16
Ctid:NCT02868970

Link: https://clinicaltrials.gov/ct2/show/NCT02868970

Conditions:Healthy
Interventions:Travel Health (Hepatitis A, Hepatitis B, Typhoid Fever)
Phase:Phase 4

Title:TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)
Status:Terminated
updateDate:2023-10-13
Ctid:NCT02608411

Link: https://clinicaltrials.gov/ct2/show/NCT02608411

Conditions:Carcinoma, Small Cell
Interventions:ARQ197
Phase:Phase 2

View More

Title:Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects
Status:Completed
updateDate:2022-09-09
Ctid:NCT01892527

Link: https://clinicaltrials.gov/ct2/show/NCT01892527

Conditions:Colorectal Cancer Metastatic|C-met Overexpression
Interventions:Tivantinib (ARQ197)
Phase:Phase 2

Title:Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years
Status:Completed
updateDate:2022-08-25
Ctid:NCT01676402

Link: https://clinicaltrials.gov/ct2/show/NCT01676402

Conditions:Influenza
Interventions:TIV
Phase:Phase 1

Title:Pazopanib and ARQ 197 for Advanced Solid Tumors
Status:Completed
updateDate:2022-07-01
Ctid:NCT01468922

Link: https://clinicaltrials.gov/ct2/show/NCT01468922

Conditions:Solid Tumor
Interventions:ARQ 197
Phase:Phase 1

Title:ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Status:Completed
updateDate:2021-04-08
Ctid:NCT01075048

Link: https://clinicaltrials.gov/ct2/show/NCT01075048

Conditions:Metastatic Colorectal Cancer
Interventions:Irinotecan
Phase:Phase 1/Phase 2

Title:Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Status:Terminated
updateDate:2021-04-06
Ctid:NCT01244191

Link: https://clinicaltrials.gov/ct2/show/NCT01244191

Conditions:Non Squamous, Non-small-cell Lung Cancer
Interventions:Erlotinib
Phase:Phase 3

Title:ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors
Status:Terminated
updateDate:2021-04-06
Ctid:NCT01055067

Link: https://clinicaltrials.gov/ct2/show/NCT01055067

Conditions:Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)
Interventions:Tivantinib (ARQ 197)
Phase:Phase 2

Title:Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
Status:Completed
updateDate:2021-04-06
Ctid:NCT01755767

Link: https://clinicaltrials.gov/ct2/show/NCT01755767

Conditions:Hepatocellular Carcinoma
Interventions:Placebo
Phase:Phase 3

Title:An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
Status:Completed
updateDate:2021-03-10
Ctid:NCT01178411

Link: https://clinicaltrials.gov/ct2/show/NCT01178411

Conditions:Advanced Solid Tumors
Interventions:Anti-Cancer Combination Therapy
Phase:Phase 1/Phase 2

Title:Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
Status:Completed
updateDate:2021-01-22
Ctid:NCT02049060

Link: https://clinicaltrials.gov/ct2/show/NCT02049060

Conditions:Malignant Pleural Mesothelioma|Nonsquamous Nonsmall Cell Neoplasm of Lung
Interventions:Tivantinib
Phase:Phase 1/Phase 2

Title:Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
Status:Completed
updateDate:2019-08-28
Ctid:NCT01447914

Link: https://clinicaltrials.gov/ct2/show/NCT01447914

Conditions:Refractory Multiple Myeloma
Interventions:Tivantinib
Phase:Phase 2

Title:Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
Status:Completed
updateDate:2019-02-12
Ctid:NCT02150733

Link: https://clinicaltrials.gov/ct2/show/NCT02150733

Conditions:Hepatic Impairment|Solid Tumor|Cancer
Interventions:Tivantinib
Phase:Phase 1

Title:Effect of Tivantinib on the QTC Interval in Cancer Subjects
Status:Completed
updateDate:2019-02-12
Ctid:NCT01699061

Link: https://clinicaltrials.gov/ct2/show/NCT01699061

Conditions:Solid Tumors
Interventions:Placebo
Phase:Phase 1

Title:Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
Status:Completed
updateDate:2019-02-12
Ctid:NCT01517399

Link: https://clinicaltrials.gov/ct2/show/NCT01517399

Conditions:Solid Tumors
Interventions:vitamin K
Phase:Phase 1

Title:Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors
Status:Completed
updateDate:2019-02-12
Ctid:NCT01149720

Link: https://clinicaltrials.gov/ct2/show/NCT01149720

Conditions:Solid Tumors
Interventions:Tivantinib (ARQ 197) Capsule D, oral
Phase:Phase 1

Title:Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
Status:Completed
updateDate:2019-01-03
Ctid:NCT01688973

Link: https://clinicaltrials.gov/ct2/show/NCT01688973

Conditions:Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma
Interventions:Tivantinib
Phase:Phase 2

Title:Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Status:Completed
updateDate:2018-12-19
Ctid:NCT01696955

Link: https://clinicaltrials.gov/ct2/show/NCT01696955

Conditions:Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Carcinoma
Interventions:Tivantinib
Phase:Phase 2

Title:Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Status:Completed
updateDate:2018-12-06
Ctid:NCT01609998

Link: https://clinicaltrials.gov/ct2/show/NCT01609998

Conditions:Influenza
Interventions:TIV
Phase:Phase 1

Title:Tivantinib in Treating Patients With Metastatic Prostate Cancer
Status:Completed
updateDate:2018-09-12
Ctid:NCT01519414

Link: https://clinicaltrials.gov/ct2/show/NCT01519414

Conditions:Hormone-Resistant Prostate Cancer|Prostate Adenocarcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer
Interventions:Tivantinib
Phase:Phase 2

Title:Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
Status:Completed
updateDate:2018-04-03
Ctid:NCT01654965

Link: https://clinicaltrials.gov/ct2/show/NCT01654965

Conditions:Adult Solid Neoplasm
Interventions:Topotecan Hydrochloride
Phase:Phase 1

Title:Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status:Completed
updateDate:2017-10-12
Ctid:NCT01749384

Link: https://clinicaltrials.gov/ct2/show/NCT01749384

Conditions:Solid Neoplasm
Interventions:Tivantinib
Phase:Phase 1

Title:A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)
Status:Completed
updateDate:2017-10-09
Ctid:NCT02029157

Link: https://clinicaltrials.gov/ct2/show/NCT02029157

Conditions:Liver Cancer
Interventions:Placebo
Phase:Phase 3

Title:ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses
Status:Completed
updateDate:2017-10-02
Ctid:NCT01682369

Link: https://clinicaltrials.gov/ct2/show/NCT01682369

Conditions:Influenza
Interventions:ATIV (Fluad)
Phase:Phase 2

Title:T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011
Status:Completed
updateDate:2017-08-21
Ctid:NCT03022422

Link: https://clinicaltrials.gov/ct2/show/NCT03022422

Conditions:Influenza
Interventions:High-Dose TIV
Phase:Phase 4

Title:T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012
Status:Completed
updateDate:2017-05-22
Ctid:NCT03022435

Link: https://clinicaltrials.gov/ct2/show/NCT03022435

Conditions:Influenza
Interventions:LAIV
Phase:Phase 4

Title:A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications
Status:Completed
updateDate:2017-04-21
Ctid:NCT01998477

Link: https://clinicaltrials.gov/ct2/show/NCT01998477

Conditions:Influenza
Interventions:TIV
Phase:Phase 3

Title:Study of ARQ 197 Monotherapy
Status:Completed
updateDate:2017-03-15
Ctid:NCT01152645

Link: https://clinicaltrials.gov/ct2/show/NCT01152645

Conditions:Gastric Cancer
Interventions:ARQ 197
Phase:Phase 2

Title:Study of ARQ 197 in Hepatocellular Carcinoma (HCC)
Status:Completed
updateDate:2017-03-03
Ctid:NCT01656265

Link: https://clinicaltrials.gov/ct2/show/NCT01656265

Conditions:Advanced Hepatocellular Carcinoma
Interventions:ARQ 197
Phase:Phase 1

Title:Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
Status:Completed
updateDate:2016-11-23
Ctid:NCT01611857

Link: https://clinicaltrials.gov/ct2/show/NCT01611857

Conditions:Malignant Solid Tumour|Gastroesophageal Cancer
Interventions:FOLFOX
Phase:Phase 1/Phase 2

Title:Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
Status:Terminated
updateDate:2016-10-24
Ctid:NCT01861301

Link: https://clinicaltrials.gov/ct2/show/NCT01861301

Title:Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
Status:Completed
updateDate:2016-09-23
Ctid:NCT02307851

Link: https://clinicaltrials.gov/ct2/show/NCT02307851

Conditions:Influenza
Interventions:Comparator TIV
Phase:Phase 2

Title:Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone
Status:Completed
updateDate:2016-03-24
Ctid:NCT01498718

Link: https://clinicaltrials.gov/ct2/show/NCT01498718

Conditions:Influenza
Interventions:TIV
Phase:Phase 1

Title:Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
Status:Completed
updateDate:2016-03-21
Ctid:NCT01575522

Link: https://clinicaltrials.gov/ct2/show/NCT01575522

Title:Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV
Status:Completed
updateDate:2016-02-23
Ctid:NCT02293317

Link: https://clinicaltrials.gov/ct2/show/NCT02293317

Conditions:Influenza
Interventions:TIV
Phase:Phase 2

Title:Safety and Reactogenicity of a PAL Combined With Seasonal Flu Vaccine in Healthy Adults
Status:Unknown status
updateDate:2016-02-12
Ctid:NCT02188810

Link: https://clinicaltrials.gov/ct2/show/NCT02188810

Conditions:Flu
Interventions:TIV
Phase:Phase 1

Title:Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
Status:Completed
updateDate:2015-10-20
Ctid:NCT01625156

Link: https://clinicaltrials.gov/ct2/show/NCT01625156

Conditions:Adult Solid Neoplasm
Interventions:Tivantinib
Phase:Phase 1

Title:ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer
Status:Completed
updateDate:2015-08-18
Ctid:NCT01580735

Link: https://clinicaltrials.gov/ct2/show/NCT01580735

Conditions:Non-small-cell Lung Cancer
Interventions:ARQ 197
Phase:Phase 2

Title:Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Status:Completed
updateDate:2015-07-02
Ctid:NCT01725191

Link: https://clinicaltrials.gov/ct2/show/NCT01725191

Conditions:Childhood Solid Neoplasm
Interventions:Tivantinib
Phase:Phase 1

Title:Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above
Status:Completed
updateDate:2014-03-12
Ctid:NCT01879553

Link: https://clinicaltrials.gov/ct2/show/NCT01879553

Conditions:Human Influenza
Interventions:TIV
Phase:Phase 2

Title:Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age
Status:Completed
updateDate:2014-03-11
Ctid:NCT01209780

Link: https://clinicaltrials.gov/ct2/show/NCT01209780

Conditions:Seasonal Influenza
Interventions:Comparator TIV
Phase:Phase 3

Title:Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults
Status:Completed
updateDate:2014-02-13
Ctid:NCT02062281

Link: https://clinicaltrials.gov/ct2/show/NCT02062281

Conditions:Pneumococcal Infection|Influenza
Interventions:23vPPV+TIV
Phase:Phase 4

Title:A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen
Status:Withdrawn
updateDate:2014-01-07
Ctid:NCT01070290

Link: https://clinicaltrials.gov/ct2/show/NCT01070290

Conditions:Gastric Cancer
Interventions:Oxaliplatin, capecitabine or irinotecan
Phase:Phase 2

Title:Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults
Status:Completed
updateDate:2013-07-29
Ctid:NCT01701752

Link: https://clinicaltrials.gov/ct2/show/NCT01701752

Conditions:Influenza A
Interventions:FP-01.1-Adjuvant
Phase:Phase 1

Title:Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults
Status:Completed
updateDate:2013-07-18
Ctid:NCT01014806

Link: https://clinicaltrials.gov/ct2/show/NCT01014806

Conditions:Influenza
Interventions:TIV
Phase:Phase 2

Title:Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
Status:Completed
updateDate:2013-02-28
Ctid:NCT00988741

Link: https://clinicaltrials.gov/ct2/show/NCT00988741

Conditions:Unresectable Hepatocellular Carcinoma
Interventions:Placebo
Phase:Phase 2

Title:A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status:Completed
updateDate:2013-02-28
Ctid:NCT00777309

Link: https://clinicaltrials.gov/ct2/show/NCT00777309

Conditions:Non Small Cell Lung Cancer
Interventions:Placebo
Phase:Phase 2

Title:A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Status:Completed
updateDate:2013-02-25
Ctid:NCT00558207

Link: https://clinicaltrials.gov/ct2/show/NCT00558207

Conditions:Pancreatic Neoplasms
Interventions:gemcitabine
Phase:Phase 2

Title:Phase 2 Study in Patients With MiT Tumors
Status:Completed
updateDate:2013-02-08
Ctid:NCT00557609

Link: https://clinicaltrials.gov/ct2/show/NCT00557609

Conditions:Renal Cell Carcinoma (RCC)|Alveolar Soft Part Sarcoma (ASPS)|Clear Cell Sarcoma (CCS)
Interventions:ARQ 197
Phase:Phase 2

Title:A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
Status:Completed
updateDate:2012-09-07
Ctid:NCT00609921

Link: https://clinicaltrials.gov/ct2/show/NCT00609921

Conditions:Cancer
Interventions:ARQ197
Phase:Phase 1

Title:A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers
Status:Completed
updateDate:2012-07-31
Ctid:NCT01010737

Link: https://clinicaltrials.gov/ct2/show/NCT01010737

Conditions:Influenza
Interventions:TIV
Phase:Phase 1/Phase 2

Title:A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
Status:Completed
updateDate:2012-07-23
Ctid:NCT00612209

Link: https://clinicaltrials.gov/ct2/show/NCT00612209

Conditions:Cancer, Advanced Solid Tumors
Interventions:ARQ 197
Phase:Phase 1

Title:A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
Status:Completed
updateDate:2012-07-23
Ctid:NCT00612703

Link: https://clinicaltrials.gov/ct2/show/NCT00612703

Conditions:Cancer
Interventions:ARQ 197
Phase:Phase 1

Title:Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
Status:Completed
updateDate:2012-07-12
Ctid:NCT00802555

Link: https://clinicaltrials.gov/ct2/show/NCT00802555

Conditions:Cirrhosis|Hepatocellular Carcinoma
Interventions:ARQ 197
Phase:Phase 1

Title:A Post Marking Study to Evaluate the Safety of FluMist in Children
Status:Completed
updateDate:2012-03-08
Ctid:NCT00569894

Link: https://clinicaltrials.gov/ct2/show/NCT00569894

Conditions:Healthy
Interventions:TIV (Injection)
Phase:

Title:Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children
Status:Completed
updateDate:2012-02-17
Ctid:NCT00192322

Link: https://clinicaltrials.gov/ct2/show/NCT00192322

Conditions:Influenza
Interventions:TIV
Phase:Phase 2

Title:Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
Status:Completed
updateDate:2012-02-17
Ctid:NCT00492557

Link: https://clinicaltrials.gov/ct2/show/NCT00492557

Conditions:Pneumococcal Infections
Interventions:13vPnC + TIV
Phase:Phase 3

Title:Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.
Status:Completed
updateDate:2012-02-14
Ctid:NCT00192309

Link: https://clinicaltrials.gov/ct2/show/NCT00192309

Conditions:Influenza
Interventions:Placebo
Phase:Phase 2

Title:ARQ 197 in Subjects With Metastatic Solid Tumors
Status:Completed
updateDate:2009-08-26
Ctid:NCT00302172

Link: https://clinicaltrials.gov/ct2/show/NCT00302172

Conditions:Cancer|Tumor
Interventions:ARQ 197
Phase:Phase 1

Title:Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers
Status:Completed
updateDate:2008-06-19
Ctid:NCT00658554

Link: https://clinicaltrials.gov/ct2/show/NCT00658554

Conditions:Healthy
Interventions:ARQ 197
Phase:Phase 1

Title:A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 1/2 STUDY OF ARQ 197 IN COMBINATION WITH IRINOTECAN AND CETUXIMAB IN SUBJECTS WITH METASTATIC COLORECTAL CANCER WITH WILD-TYPE KRAS WHO HAVE RECEIVED FRONT-LINE SYSTEMIC THERAPY
Status:Completed
Date:2010-06-15
Eudractnumber:2009-016025-34

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016025-34

Condition:Treatment for metastatic colorectal cancer (CRC) in combination with irinotecan and cetuximab after failure of front-line systemic therapy in subjects with wild-type KRAS alleles.
Phase:Phase 2

Title:MULTICENTER PHASE 2 TRIAL OF ARQ 197 FOR SUBJECTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS
Status:Completed
Date:2010-03-04
Eudractnumber:2009-015400-26

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015400-26

Condition:Germ cell tumors (GCT) including testicular and non-central nervous system (non-CNS) extragonadal types.
Phase:Phase 2

Title:A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients with Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
Status:Completed
Date:2009-10-22
Eudractnumber:2008-007155-27

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007155-27

Condition:Unresectable hepatocellular carcinoma (HCC)
Phase:Phase 2

Title:A Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Associated Tumors
Status:Completed
Date:2009-09-18
Eudractnumber:2009-011669-10

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011669-10

Condition:Microphthalmia Transcription Factor Associated Tumors:Clear cell sarcomaAlveolar soft part sarcomaTranslocation associated renal cell carcinoma (Renal cell carcinoma;MedDRA code manually entered in E.1.2)
Phase:Phase 2

Title:A Randomized Phase 2 Study of Erlotinib plus ARQ 197 versus Erlotinib plus Placebo in Previously Treated Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status:Completed
Date:2008-07-09
Eudractnumber:2007-004634-17

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004634-17

Condition:Non-Small Cell Lung Cancer (phase 3b/4)
Phase:Phase 2

Title:A Randomized Phase 2 Study of ARQ 197 versus Investigator's Choice of Second-Line Chemotherapy in Patients with Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment with One Prior Chemotherapy Regimen
Status:Prematurely Ended
Date:2008-02-05
Eudractnumber:2007-004622-25

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004622-25

Condition:Locally Advanced or Metastatic Gastric Cancer
Phase:Phase 2

Title:A Randomized Phase 2 Study of ARQ 197 versus Gemcitabine in Treatment-naïve Patients with Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Status:Prematurely Ended
Date:2007-11-06
Eudractnumber:2007-002727-32

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002727-32

Condition:Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Phase:Phase 2